http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110129372-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15043 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-90 |
filingDate | 2019-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2021-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-110129372-B |
titleOfInvention | Construction method of RFFT1 cells |
abstract | The invention provides a construction method of RFFT1 cells, and belongs to the technical field of biology. The invention constructs the T cell with integrated attack and defense, high accuracy and high killing property. The construction method comprises the following steps: the PBMC cells are loaded with polypeptide causing tumor mutation, and then polypeptide impact is carried out on the PBMC cells loaded with the polypeptide; performing expanded culture after impact to obtain FF cells; so that the tumor-mutated polypeptide is used as an antigen to directly stimulate FF cells to screen precise polypeptide; culturing PBMC cells, and performing multiple impacts by using the accurate polypeptide in the culture process; continuing culturing after impacting to obtain RFF cells; screening to obtain specific cells capable of identifying the precision polypeptide; obtaining a TCR gene from a specific cell; culturing PBMC (peripheral blood mononuclear cell), knocking out the original TCR gene and the surface immunosuppressive signal molecule, and transferring the obtained TCR gene to prepare an RFFT cell; and (3) carrying out immunosuppressive signal molecule blocking on the obtained RFFT cells by using a monoclonal antibody medicine to obtain the RFFT1 cells. |
priorityDate | 2018-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 95.